Hi Hoy,
Everybody & his dog are trying to fix wet AMD, so that won't generate much new investor interest , IMO.
Wet is a popular target because the eye is a fairly protected organ from mistakes escaping back into the rest of the body. Its presently treated with 1-2 monthly injections to stop bleeding in the subretinal space.
I'm not clear what Benitec are saying about Dry AMD, the much more common disease - fore-runner of wet AMD. Dry is a huge market in the aged population, but neither are life threatening. If they are the only ones chasing Dry, I think they'd need to spell it out louder & clearer. They do list 2 targets.
What are the goals? Just halt it from getting worse or restore back to normal? Wet AMD causes quite a bit of physical damage to the base layer of the macular by buckling it out of shape.
Its all a large market, but they'd need a more catchy song to woo US investors.
I'm pretty sure they could do the clinical trials anywhere in the US, UK, Europe, 'ere or Asia. All blindness charities & governments are aware of the risk to over 50's.
I think we inherited BLT's technology from Tacere. Maybe they did some safety in vitro & in vivo with mice & rats in UK. But I think its a human only disorder caused by hard to identify mutations. Benitec seem to be saying: This peculiarity seems to manifest in most AMD disorders, so lets knock it out in every patient, or that's how I read it, but I'm no scientist.
Bit of a bummer of a day, Cheers, Japes.
- Forums
- ASX - By Stock
- BLT
- Updated listing price
Updated listing price, page-35
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online